News – Page 7 – Alligator Bioscience

2023-08-21

Regulatory

Alligator Bioscience Receives European Medicine Agency Orphan Designation for Mitazalimab in Pancreatic Cancer

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the European Medicines Agency (EMA) has granted Orphan De ...

2023-08-17

The exercise period for Alligator’s warrants of series TO 6 begins today

Today, on August 17, 2023, the exercise period for warrants series TO 6 in Alligator Bioscience AB (publ) ("Alligator" or the ...

2023-08-17

Alligator Bioscience announces resignation of Malin Carlsson as Chief Operating Officer

Lund, Sweden, August 17, 2023 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the resignation of Malin Carlsson as th ...

2023-08-15

Exercise price determined for the exercise of warrants of series TO 6 in Alligator Bioscience AB

Alligator Bioscience AB (publ) (“Alligator” or the “Company”) hereby announces that the exercise price for warrants series TO 6 (the “warran ...

2023-07-31

Alligator Bioscience announce milestone achievement in 2021 Immuno-Oncology Research Collaboration and License Agreement with Orion Corporation

Technical Feasibility achieved in second collaboration project triggering new milestone payment to Alligator Collaboration aims to discover ...

2023-07-13

Regulatory

Alligator Bioscience AB reports financial results for H1 2023 and Q2 2023 and provides a business update

Positive second interim analysis from OPTIMIZE-1 Phase 2 study shows increase in ORR* and favorable DoR** suggesting durable benefits of mit ...

2023-07-11

Alligator Bioscience to Present its CD40 Program at the 3rd Annual Tumor Myeloid-Directed Therapies Summit in July 2023

Presentation highlights very promising interim efficacy analysis from mitazalimab OPTIMIZE-1 Phase 2 study in pancreatic cancer Latest analy ...

2023-07-05

Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB

Alligator Bioscience AB (publ) today announces that Anette Sundstedt, PhD, Principal Scientist at Alligator, has been appointed as employee ...

2023-06-302023-07-03

Phase 2 results indicate durability of response for Alligator’s CD40 agonist

BioStock interview with Alligator CMO, Sumeet Ambarkhane. Following the second round of interim results from OPTIMIZE-1, the phase 2 trial w ...